Drugs / [11C]OMAR
[11C]OMAR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05683184 | Mar 2023 → Dec 2027 expected | substance-related disorder | Yale University | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 0 | NCT03204305 Comparator | Sep 2017 → Mar 2020 | cannabis dependence | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT07800520 Background | Oct 2026 → Aug 2030 expected | substance-related disorder | Yale University | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [11C]OMAR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05683184 ↗ |
| Known as | 11c-jhu 75528 | ChEMBL registry synonym — accepted as the source's own label CHEMBL514215 ↗ |
| Known as | [11c]nida41020 | ChEMBL registry synonym — accepted as the source's own label CHEMBL514215 ↗ |
| Known as | JHU-75528 C-11 | ChEMBL registry synonym — accepted as the source's own label CHEMBL514215 ↗ |
| Known as | Omar c-11 | ChEMBL registry synonym — accepted as the source's own label CHEMBL514215 ↗ |
| Modality | Diagnostic / imaging agent | “a PET radiotracer that binds to cannabinoid type 1 receptors (CB1R).” NCT03204305 ↗ |